Nivolumab + ipilimumab (Opdivo and Yervoy)

Nivolumab + ipilimumab at a glance

Nivolumab and ipilimumab are two immunotherapy medicines given together in selected cancer treatment plans. Opdivo is a brand of nivolumab; Yervoy is the brand of ipilimumab. They are normally given as separate intravenous infusions during the combination phase. The dose balance, visit pattern and duration depend on the particular plan.

This guide covers the two-drug immunotherapy combination and any planned nivolumab-only continuation. Keep your personal calendar with it. If another anticancer medicine is part of your prescription, you also need instructions for that medicine.

How the combination works

Nivolumab blocks PD-1 and ipilimumab blocks CTLA-4. These are checkpoints that help control immune-cell activity. Blocking two checkpoints can help the immune system recognise and attack cancer, but can also cause it to inflame healthy organs.

The combination is not simply two doses of the same treatment. Each component has a separate role, and the prescribed balance matters. A severe immune reaction is not evidence that treatment is more effective; it is a medical problem needing prompt assessment.

How the team decides whether it is suitable

Your oncologist considers the precise cancer type, stage, earlier treatment, relevant tumour tests and general health. This combination is used in several established settings, but eligibility and biomarker requirements differ. Ask which features of your cancer support the recommendation.

Discuss inflammatory bowel disease, other autoimmune conditions, lung or heart problems, previous organ or donor stem-cell transplantation and any serious reaction to earlier immunotherapy. The team also considers whether you can reach urgent care if symptoms develop between visits. International prescribing information is a scientific reference rather than a statement of Indian approval or availability.

Before treatment starts

Your team will ask about autoimmune conditions, previous organ or donor stem-cell transplantation, lung or heart disease, infections and earlier cancer treatment. Mention previous severe reactions to any immunotherapy, even if you are now well. Tell them about pregnancy, breastfeeding, any possibility of pregnancy and whether you want to discuss fertility preservation before starting.

Bring a complete medicines list, including inhalers, eye drops, steroid creams, tablets, injections, vitamins and traditional or herbal remedies. A medicine taken only occasionally can still matter. Do not stop prescribed steroids or immune-suppressing treatment yourself; the team must weigh why you need them and how they fit with treatment.

Baseline tests usually include blood counts, kidney and liver function, blood sugar and thyroid function. Other hormone tests, heart tests or infection screening depend on your history and treatment plan. Record your usual bowel pattern, breathing, energy level and any existing rash. This makes it easier to identify a change rather than attributing everything to cancer.

Before leaving the first appointment, know how to reach your own hospital’s urgent oncology service, including outside clinic hours. Keep the treatment alert card or an up-to-date medicine record with you. A family member can help remember instructions and recognise changes you may not notice yourself.

How treatment is given

A trained nurse gives the medicines through a suitable intravenous line, with nivolumab before ipilimumab when both are due. Each infusion may take about 30 minutes under the relevant protocol, but preparation, assessment, line flushing and observation add time. Some product instructions or clinical circumstances require longer. Report infusion symptoms immediately.

Some common plans give both medicines every three weeks for up to four doses, then continue nivolumab alone. Other plans give nivolumab every two or three weeks and ipilimumab every six weeks. These patterns are not interchangeable. Your calendar should clearly mark which medicine is due on each date.

After an initial combination phase, intravenous nivolumab may be given every two or four weeks in appropriate schedules. The team determines total duration; do not assume that every indication has the same maximum number of months. If blood tests or symptoms make treatment unsafe, a dose may be delayed or treatment stopped rather than reduced.

A separate under-the-skin nivolumab formulation exists in some countries. Formulation eligibility depends on the exact label and phase: it must not automatically replace intravenous nivolumab while ipilimumab is being given. Certain authorised maintenance uses after intravenous combination treatment are distinct from concurrent administration. Ask the pharmacist to confirm any proposed switch.

Tell the nurse about flushing, itching, chills, dizziness, chest or back discomfort, breathlessness or swelling. Staff can interrupt treatment and manage a reaction. If the line hurts, leaks or becomes swollen, tell them immediately. For a missed appointment, phone the unit rather than changing your own schedule.

Monitoring and checking response

Before treatment, staff review symptoms and blood results to check that another dose is appropriate. Some immune problems first appear on a blood test, before you feel unwell. Thyroid, liver, kidney or glucose abnormalities may need repeat tests, additional investigations or another specialist’s advice.

Scans and, where appropriate, other disease measurements assess whether treatment is helping. Feeling well or having side effects cannot reliably tell you whether it is working. Occasionally immune inflammation complicates the interpretation of a scan; your oncologist decides whether a repeat scan or other assessment is appropriate. Worsening symptoms should still be reported promptly.

A dose may be delayed while a new symptom is investigated. Checkpoint antibodies are commonly withheld or stopped for significant toxicity rather than simply reduced to a smaller dose. This is a safety decision, not evidence that you have done anything wrong. The team balances cancer control with recovery and the risk of the same reaction happening again.

Common side effects and practical care

Side effects vary with the medicine, your health and any accompanying treatment. You may have several, a few or none. The effects described below can occur with this combination. Serious immune inflammation can sometimes begin with what seems like a mild everyday symptom. Frequency varies, so this guide does not attach a single percentage to effects across different treatment settings.

Tiredness and reduced energy

Plan demanding tasks for the time of day when you feel best, accept practical help and include gentle activity if you can. Rest is useful, but spending the entire day in bed can make weakness worse. A sudden increase in tiredness, dizziness or inability to manage normal activities needs assessment for anaemia, infection or hormone problems rather than being accepted as inevitable.

Skin rash and itching

Use a plain moisturiser, lukewarm water and comfortable clothing. Protect your skin from strong sunlight. Let the team know about a new rash; photographs can help show how it changes. Do not use a new medicated cream without checking. Blisters, peeling skin, mouth sores or a painful widespread rash need urgent help.

Loose stools or diarrhoea

Note how many times you pass stool compared with your normal pattern, whether it wakes you at night and whether there is pain, mucus or blood. Keep drinking unless you have a fluid restriction. Contact your team promptly for new or increasing diarrhoea. Do not repeatedly suppress it with over-the-counter medicines before the team has considered immune bowel inflammation.

Nausea, appetite changes and constipation

Small, regular meals and prescribed anti-sickness medicines may help. Ask for dietetic support if weight is falling or eating is difficult. Constipation can be related to other medicines or reduced activity; discuss an appropriate laxative rather than straining. Persistent vomiting, a swollen abdomen, severe pain or inability to keep fluids down requires urgent advice.

Muscle and joint discomfort

Gentle movement, pacing and the team’s recommended pain relief can help. Check before taking ibuprofen or similar anti-inflammatory medicines, especially with kidney problems or other treatment. New marked weakness, drooping eyelids, difficulty swallowing or dark urine is different from ordinary aching and needs urgent assessment.

Important side effects to recognise

Checkpoint treatment can make the immune system inflame healthy organs. Several organs can be affected together. Problems may appear during treatment or after it stops, and a symptom does not have to be dramatic to deserve attention.

Lung inflammation

New cough, breathlessness or chest discomfort can reflect inflammation called pneumonitis, infection or another problem. Contact the team promptly. Severe breathlessness, blue lips, collapse or difficulty speaking because of breathing requires emergency care.

Bowel and liver inflammation

Immune colitis can cause diarrhoea, cramps, blood or mucus, and occasionally serious bowel damage. Liver inflammation may initially show only on blood tests. Yellow eyes or skin, dark urine, right-sided upper abdominal pain or unusual bruising needs prompt assessment. Do not assume an existing digestive or liver condition explains a new change.

Hormone gland problems and diabetes

Thyroid, pituitary or adrenal inflammation can cause unusual tiredness, headache, feeling cold, weight changes, dizziness or altered mood. New excessive thirst and frequent urination can signal diabetes. Vomiting with marked thirst, deep or rapid breathing, confusion or severe weakness is an emergency. Some hormone deficiencies require long-term replacement even after the immune inflammation settles.

Kidney, heart, muscle and nerve problems

Reduced urine, blood in the urine or swelling may indicate kidney injury. Chest pain, palpitations, faintness, rapid weakness, swallowing difficulty, confusion or a seizure can signal serious heart or nervous-system effects. Heart, muscle and nerve inflammation can overlap. Do not wait for all the symptoms in a list to appear.

Eye problems, severe skin reactions and transplant complications

Eye pain, light sensitivity or new blurred vision needs urgent advice. Severe rash with blistering, peeling or mouth involvement needs immediate assessment. Checkpoint activation can also cause transplant rejection or complications around a donor stem-cell transplant. Tell every treating specialist that you have received this medicine.

How immune side effects are treated

Treatment may involve temporarily withholding immunotherapy, corticosteroids, hormone replacement or other specialist medicines. Severe reactions sometimes require hospital care and permanent discontinuation. Take the steroid taper exactly as prescribed; stopping abruptly can be dangerous. Early reporting often makes management more straightforward, but no one can promise that every effect will completely reverse.

The oncology team may involve an organ specialist. Bring your treatment alert card to emergency assessment; an emergency department may not have access to the cancer clinic’s records. Tell staff about current steroids and the last immunotherapy date. Do not wait for your next infusion appointment to report a problem.

Other medicines and vaccinations

Check new prescriptions, non-prescription medicines, supplements and herbal products with the cancer team or pharmacist. Avoid products marketed as “immune boosters”: they are not proven substitutes for treatment and can complicate safety assessment. Do not assume a natural product is harmless.

Steroids may be essential to treat immune side effects, despite the medicine’s aim of activating immunity. Never withhold necessary steroids because you are worried they will cancel the treatment. Equally, do not start leftover steroid tablets yourself. If you require hormone replacement or long-term steroids, carry the relevant alert information.

Discuss influenza, COVID-19 and other vaccines with the team. Non-live vaccines are often appropriate, but timing and response depend on the full treatment, particularly immune-suppressing medicines. Live vaccines need specific specialist approval. There is no single post-treatment vaccine waiting period that is correct for every checkpoint-treated patient.

Everyday life during treatment

Eating does not alter the dose of a medicine given by infusion or injection. Aim for adequate fluids and regular food, adjusting for nausea or diarrhoea, and follow any kidney, heart or diabetes advice already in place. Avoid restrictive diets or supplements promising to improve immune treatment response.

Work and exercise can continue if you feel able, with flexibility around appointments and fatigue. Start activity gently and reduce it when unwell. Do not drive if you are dizzy, sleepy, weak, visually affected or unable to concentrate. Premedicines and pain medicines can also impair driving. Sudden neurological symptoms require assessment, not simply a rest before driving again.

Discuss travel before booking, especially long journeys or places far from emergency care. Keep your treatment record, medicines list and enough prescribed medicines with you. Tell dentists and other clinicians about immunotherapy before procedures. Wash hands, avoid close contact with people who are clearly infectious and use food safety precautions; complete isolation is not usually necessary solely because you are receiving a checkpoint inhibitor.

Sex is generally possible if comfortable, with the contraception precautions below. Symptoms, dryness or fatigue may affect intimacy and can be discussed without embarrassment. Emotional support can help with uncertainty between scans; report persistent anxiety, poor sleep or low mood rather than carrying it alone.

Fertility, pregnancy and breastfeeding

If you could become pregnant, use effective contraception during the whole treatment course and for at least five months after the final nivolumab dose. US ipilimumab information specifies three months after its final dose; follow whichever applicable end date is later. Continuing nivolumab usually determines that later date. Have the team record your actual contraception end date, especially if one drug stops earlier. Pregnancy testing is needed before treatment when relevant.

Do not breastfeed during treatment. US nivolumab information advises avoiding breastfeeding for five months after its final dose, and US ipilimumab information specifies three months after its final dose. Follow the later applicable end date. Discuss the applicable product leaflets and a feeding plan with your team. Tell them immediately about possible pregnancy or contraceptive failure rather than waiting for a routine visit.

Effects on future fertility are not fully understood. Discuss preservation before treatment if future parenthood matters to you. Advice for a male partner is not automatically the same as the interval for someone who can become pregnant; ask for an individual plan.

After a pause or the end of treatment

Keep attending the follow-up appointments and tests recommended by your team. Immune side effects can start after the final dose, so continue to mention previous immunotherapy when seeking medical care. Keep your alert card or treatment summary accessible and tell emergency staff about the medicine even months later.

Continue prescribed hormone replacement, steroid tapering and other supportive treatment. Do not stop these because the anticancer infusion has finished. Follow the specified contraception and breastfeeding restrictions from the date of the final relevant dose. Recovery is individual; ask for rehabilitation, nutritional support or help returning to work if symptoms persist.

Frequently asked questions